Strategic expansion Codis is expanding through the acquisition of Catalent's UK facilities, including Nottingham, to create Europe’s leading end-to-end spray drying capability. This presents cross-sell opportunities for integrated spray drying, ASD development, and particle engineering services to existing Catalent and Codis customers, as well as new EU-based pharma clients seeking scale.

Global commercial leadership Recent CCO appointment and strengthened Sales Marketing and Business Development leadership across US and UK indicate a sharpened global commercial strategy. This signals readiness to pursue enterprise-level, multi-region CDMO partnerships and longer-term contracts with strategic pharma accounts.

Core capabilities Codis specializes in spray drying, amorphous solid dispersions, and advanced particle engineering. These core capabilities align with suppliers and manufacturers needing formulation stability, rapid scale-up, and high-performance drug delivery solutions, offering opportunities to upsell process development and manufacturing services.

Industry focus Operating as a pharmaceutical manufacturing CDMO with a global footprint and regulatory track record positions Codis to target mid-to-large biotech and pharma companies seeking compliant, scalable production for complex formulations, including small-scale to commercial-scale OSD processes.

Digital and talent levers Adoption of modern tech stack and investment in leadership talent like the Senior VP of Sales & Marketing and new CCO show a data-driven, customer-centric approach. This enables targeted outreach, personalized account plans, and accelerated onboarding for new clients in Europe and North America.